RS-2024-00332803

Development of ○○○ inhibitor as a novel therapy for Aged-Macular degeneration

Gachon University

OPHTHALMOLOGY | **Hit**

Product Type	Small molecule
Indication	Wet-AMD
Target	Undisclosed
MoA(Mechanism of Action)	1) Binds directly to target protein, inhibiting its enzymatic activity 2) Induces target protein degradation in a proteasome-dependent manner 3) Inhibits AKT activation in human retinal microvascular endothelial cells (HRMEC) by blocking the specific receptor-mediated signaling 4) Inhibits proliferation, migration, and tube formation of HRMEC
Competitiveness	1) Novel target molecule for wet-AMD 2) The most potent inhibitor of target protein reported to date 3) Dual function of inhibiting retinal vascular cell proliferation and blocking immune cell activation 4) Overcomes problems with existing antibody therapies (e.g., unresponsiveness, fibrosis, and eye injection) through development of novel small molecules
Development Stage	Hit
Route of Administration	1) Intravitreal or eye drop 2) Oral administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund